Abstract:OBJECTIVE:To investigate the role of transforming growth factor beta(1) (TGF-beta(1)) in the pathogenesis of bronchial asthma in children and assess the effect of montelukast sodium (leukotriene receptor antagonist) on TGF-beta(1) levels.METHOD:A 12 weeks single-blind, placebo-controlled trail was conducted in 60 children with mild persistent asthma [aged 5 - 14 years, mean (7.10 ± 0.27) years]. Patients were randomly assigned to receive 5 mg montelukast sodium or placebo for 12 weeks. And 30 healthy control children [aged 5 - 14 years, mean (7.60 ± 0.25) years] were also recruited in this study from Sep. 2009 to Sep. 2010. Clinical effects and pulmonary function were evaluated before and 12 weeks after treatment. The mRNA expression of TGF-beta(1) in the peripheral blood mononuclear cells was detected by using RT-PCR with beta-actin as internal control. The percentage of the different subpopulations of Foxp(3)(+)CD4(+) T cells was assayed by 4-color flow cytometric analysis system and the levels of TGF-beta(1) in plasma by ELISA.RESULT:(1) The basic characteristics between asthma group and healthy group had no significant difference. (2) Following treatment, there was significant increase in pulmonary function in asthmatic children. The effect in the group of montelukast sodium was superior to that of placebo group (P < 0.05). (3) The serum expression of TGF-beta(1) in asthmatic children was lower than that in control group (q = 20.01, P < 0.01); after 12 weeks of treatment, the mean expression of TGF-beta(1) was (20.03 ± 1.14) ng/L for montelukast sodium group and (12.10 ± 3.91) ng/L for placebo group (P < 0.05). (4) The mRNA expression of TGF-beta(1) in asthma children was lower than that in control group (0.31 ± 0.07 vs 0.61 ± 0.2, q = 8.97, P < 0.05); after 12 weeks of treatment, the mean expression of TGF-beta(1) was (0.46 ± 0.13) for montelukast sodium group and (0.32 ± 0.04) for placebo group (q = 8.25, P < 0.05). (5) It was shown that the total Foxp(3)(+)CD(4)(+) cell percentage was higher in asthmatic children than those of control group (8.30% ± 1.30% vs 6.05% ± 1.80%); the proportion of the three subpopulation was different between groups: CD(45) RA(+)Foxp(3)(lo) was higher in asthmatic group (4.60% ± 1.04% vs 3.27% ± 1.03%) and CD(45) RA(-)Foxp(3)(hi) was lower (0.75% ± 0.13% vs 0.93% ± 0.26%); while CD(45) RA(-)Foxp(3)(lo) had no significant difference among groups (2.40% ± 0.83%, 1.61% ± 1.10%). After 12 weeks of treatment, the percentage of CD(45) RA(-)Foxp(3)(hi) was increased in montelukast sodium group compared with placebo group (1.16% ± 0.24% vs 0.89% ± 0.22%). (6) Spearman correlation analysis revealed that TGF-beta(1) levels had no correlation with the levels of pulmonary function.CONCLUSION:The protein and mRNA expression level of TGF-beta(1) was low in those asthmatic children. Insufficient secretion of TGF-beta(1) and the defective ability of activated regulatory T cells (CD(45) RA(-)Foxp(3)(hi)) in Foxp(3)(+)CD(4)(+) Treg cells might play an important role in pathogenesis of asthma. Up-regulation of the expression of TGF-beta(1) and induction of the expression of CD(45) RA(-)Foxp(3)(hi) in Foxp(3)(+)CD(4)(+)Treg cells by montelukast sodium may be one of the immunomodulatory mechanisms in asthma.

Effect of leukotriene receptor antagonist on anti-inflammation and immune func-tion in asthmatic patients

Effect of montelukast on the apoptosis of eosinophil in bronchoalveloar lavage fluid

Changes of Eosinophils in Bronchoalveolar Lavage Fluid of Asthma in Children and the Modulation Effect of Montelukast

Effect of Leukotriene Antagonist on NF-kappa B and AP-1 Activities and Levels of Interleukin-4, Interleukin-5 and Interleukin-10 with Steroid-resistant or Steroid-dependent Asthma

Effect of Leukotriene Receptor Antagonist on IL-10 Experession in the Lungs of Asthmatic Mice

Effect of montelukast and dexamethasone on inflammation of asthma

Effect of leukotrienes receptor antagonist on the expressional levels of matrix metalloproteinase- 9 and its inhibitor TIMP- 1 in rats with asthma

The Efficacy of Montelukast on the Airway Hyperresponsiveness in Children with Asthmatic Bron-chitis

Study on Cysteinyl Leukotriene Receptor Antagonist Depressing Acute Asthma Airway Inflammation

Effect of Montelukast Sodium on TGF-beta1 of Peripheral Blood Mononuclear Cells from Children with Mild Persistent Asthma

Effects of montelukast in asthma patients combined with allergic rhinitis:meta-analysis

Effect of Antagonist of Leukotrienes Receptor on Serum IL-5 Expression in Asthma-A Meta Analysis

Effect of long time oral montelukast on pulmonary function and allergy index of patients with slight and moderate asthma

[The Effect of Antianaphylaxis Drugs on Specific IgE and Eosinophil in Serum of Patients with Allergic Rhinitis].

Effect of Leukotriene Receptor Antagonist on HMGB1 Expression in the Lungs of Asthmatic Mice

Comparison of Leukotriene Receptor Antagonist and Theophylline in Addition to Inhaled Corticosteroid in Adult Asthma: A Meta-Analysis

Effect of inhaled glucocorticoid and leukotriene receptor on IL-6 expression in the lungs of asthmatic mice

The Efficacy of Montelukast Combined with Budesonide in Asthma Patients and the Combination’s Effects on the Patients’ Immune and Pulmonary Functions

Effects of oral montelukast on pulmonary function and clinical symptoms in acute asthma exacerbations: a randomized, double-blind, placebo-controlled trial

Research Progress of Cysteinyl Leukotriene Antagonist Montelukast

The effects of leukotriene receptor antagonist on TIMP-1expression in lung tissue of the asthmatic model